Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
MDT

MDT - Medtronic PLC Stock Price, Fair Value and News

85.64USD+0.58 (+0.68%)Market Closed
Watchlist

Market Summary

USD85.64+0.58
Market Closed
0.68%

MDT Stock Price

View Fullscreen

MDT RSI Chart

MDT Valuation

Market Cap

113.9B

Price/Earnings (Trailing)

27.73

Price/Sales (Trailing)

3.56

EV/EBITDA

15.46

Price/Free Cashflow

28.15

MDT Price/Sales (Trailing)

MDT Profitability

EBT Margin

17.01%

Return on Equity

7.98%

Return on Assets

4.56%

Free Cashflow Yield

3.55%

MDT Fundamentals

MDT Revenue

Revenue (TTM)

32.0B

Rev. Growth (Yr)

5.26%

Rev. Growth (Qtr)

3.66%

MDT Earnings

Earnings (TTM)

4.1B

Earnings Growth (Yr)

112.88%

Earnings Growth (Qtr)

14.05%

Breaking Down MDT Revenue

Last 7 days

-0.7%

Last 30 days

-3.4%

Last 90 days

12.9%

Trailing 12 Months

0.9%

How does MDT drawdown profile look like?

MDT Financial Health

Current Ratio

2.29

Debt/Equity

0.46

Debt/Cashflow

0.23

MDT Investor Care

Dividend Yield

3.2%

Dividend/Share (TTM)

2.74

Buy Backs (1Y)

0.04%

Diluted EPS (TTM)

3.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202330.8B31.2B31.6B32.0B
202231.8B31.7B31.1B30.8B
202127.9B30.1B31.6B31.8B
202031.1B28.9B27.9B27.9B
201930.6B30.6B30.7B30.9B
201829.7B30.0B29.9B30.4B
201729.4B29.7B29.9B29.6B
201628.6B28.8B28.7B29.0B
201517.5B20.3B23.3B26.0B
201416.9B17.0B17.2B17.4B
201316.5B16.6B16.7B16.8B
2012016.2B16.3B16.4B

Tracking the Latest Insider Buys and Sells of Medtronic PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
kirk jennifer m
sold (taxes)
-102,096
88.09
-1,159
chief accounting officer
Dec 19, 2023
wall brett a.
sold
-410,604
82.17
-4,997
evp & pres neuroscience
Dec 11, 2023
fong ivan k
sold (taxes)
-154,891
79.35
-1,952
evp general counsel & secr
Dec 08, 2023
fong ivan k
sold (taxes)
-56,757
79.27
-716
evp general counsel & secr
Dec 08, 2023
salmon sean
sold (taxes)
-34,482
79.27
-435
evp & president cardiovascular
Dec 08, 2023
white robert john
sold (taxes)
-29,250
79.27
-369
evp & pres. medical surgical
Dec 08, 2023
wall brett a.
sold (taxes)
-34,482
79.27
-435
evp & pres neuroscience
Aug 23, 2023
smith gregory l
sold
-838,400
83.84
-10,000
evp global ops & supply chain
Aug 14, 2023
wall brett a.
sold
-83,380
83.38
-1,000
evp & pres neuroscience
Aug 04, 2023
marinaro michael
sold
-113,717
84.11
-1,352
evp & president, surgical ou

1–10 of 50

Which funds bought or sold MDT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 22, 2024
Dodge & Cox
reduced
-1.23
20,630,500
558,525,000
0.36%
Feb 22, 2024
Scarborough Advisors, LLC
new
-
8,571
8,571
-%
Feb 22, 2024
AUXIER ASSET MANAGEMENT
reduced
-0.17
570,906
12,108,800
1.96%
Feb 22, 2024
Sentry LLC
new
-
1,121,030
1,121,030
0.24%
Feb 21, 2024
V-Square Quantitative Management LLC
added
177
705,260
1,073,080
0.19%
Feb 21, 2024
American Trust
added
2.8
66,864
894,894
0.07%
Feb 21, 2024
Raleigh Capital Management Inc.
reduced
-3.54
21,033
1,520,500
0.71%
Feb 21, 2024
SMITH SHELLNUT WILSON LLC /ADV
reduced
-14.13
-28,095
260,897
0.15%
Feb 20, 2024
Wellington Wealth Strategies, LLC.
new
-
423,722
423,722
0.36%
Feb 20, 2024
POLEN CAPITAL MANAGEMENT LLC
added
23.74
18,741,400
81,021,100
0.20%

1–10 of 47

Are Funds Buying or Selling MDT?

Are funds buying MDT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MDT
No. of Funds

Unveiling Medtronic PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.52%
126,545,940
SC 13G/A
Feb 12, 2024
blackrock inc.
8.9%
118,570,867
SC 13G/A
Feb 15, 2023
blackrock inc.
9.2%
122,349,678
SC 13G/A
Feb 09, 2023
vanguard group inc
9.41%
125,126,702
SC 13G/A
Feb 01, 2022
blackrock inc.
8.0%
107,903,361
SC 13G/A
Feb 10, 2021
vanguard group inc
8.27%
111,286,018
SC 13G/A
Feb 03, 2021
wellington management group llp
2.87%
38,648,749
SC 13G/A
Jan 29, 2021
blackrock inc.
7.96%
107,107,760
SC 13G/A
Feb 12, 2020
vanguard group inc
8.55%
114,617,479
SC 13G/A
Feb 05, 2020
blackrock inc.
8.2%
109,561,921
SC 13G/A

Recent SEC filings of Medtronic PLC

View All Filings
Date Filed Form Type Document
Feb 23, 2024
4
Insider Trading
Feb 21, 2024
144
Notice of Insider Sale Intent
Feb 20, 2024
8-K
Current Report
Feb 14, 2024
5
Insider Trading
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
4
Insider Trading
Dec 20, 2023
4
Insider Trading
Dec 19, 2023
144
Notice of Insider Sale Intent

What is the Fair Value of MDT?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Medtronic PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.9B
40.1B
0.08% 5.41%
36.32
5.18
-8.12% -17.45%
71.1B
19.5B
1.90% -2.48%
56.63
3.65
4.02% -22.04%
24.3B
3.8B
13.67% -2.23%
66.92
6.38
-1.48% -28.97%
21.6B
14.9B
3.05% 1.38%
8.13
1.45
2.01% 209.17%
MID-CAP
10.4B
12.7B
2.56% -12.12%
23.32
0.82
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.56
3.71
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.8
2.68
4.97% 18.89%
7.2B
3.9B
-8.15% -6.44%
-32.81
1.83
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-288.8
10.11
42.19% 84.12%
2.7B
6.6B
-4.32% -4.67%
13.36
0.41
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.4
0.33
7.95% -543.98%
380.2M
163.3M
8.18% -20.52%
-15.47
2.33
7.14% -56.09%
231.2M
329.5M
3.17% -52.24%
-16.38
0.7
0.49% 64.22%
69.6M
50.3M
4.50% -30.54%
-4.59
1.38
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.36
1.19
5.77% 8.23%

Medtronic PLC News

Latest updates
AmericanBankingNEWS22 hours ago
GuruFocus.com21 Feb 202408:52 am
Yahoo Finance06 Feb 202408:00 am

Medtronic PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue3.7%7,9847,7028,5457,7277,5857,3718,0897,7637,8477,9878,1887,7757,6476,5075,9987,7177,7067,4938,1467,5467,481
  S&GA Expenses2.8%2,6862,6132,6162,6152,6172,5672,5692,5612,6152,5472,5952,5372,6002,4172,3592,5872,6202,5432,6202,5962,605
EBITDA Margin-1.5%0.28*0.28*0.28*0.28*0.29*0.29*0.28*0.27*0.26*0.24*0.25*0.22*---------
Interest Expenses21.6%180148187167118164143137136137142143470171162156165609718243241
Income Taxes0.5%40240036314695911211010617664.00200-59.0031.0093.00-434-340-77.0010011099.00235
Earnings Before Taxes9.8%1,3131,1961,5511,3751,3951,0441,6021,5891,4938331,5661,2205255842051,5791,2949771,2921,3701,355
EBT Margin-2.7%0.17*0.17*0.17*0.18*0.18*0.18*0.17*0.17*0.16*0.13*0.13*0.09*---------
Net Income14.1%9097971,1791,2224279311,4791,4801,3177691,3561,2704944916461,9151,3718771,1721,2691,115
Net Income Margin11.9%0.13*0.11*0.12*0.13*0.14*0.17*0.16*0.15*0.15*0.12*0.12*0.10*---------
Free Cashflow-61.6%2005212,0821,2425996571,6681,8981,4989141,3681,993---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.8%90,08790,77690,94894,13493,24189,91490,98191,80491,75691,80293,08397,27095,88693,90690,68992,82291,05391,26889,69488,73088,150
  Current Assets1.0%22,08121,86921,67525,36425,39822,13523,05923,30322,73122,43422,54826,34726,03624,50922,03124,04322,65322,70521,96720,87721,653
    Cash Equivalents-2.1%1,3111,3391,5434,5214,8282,1403,7143,4792,9003,0043,5935,0776,4206,4994,1403,7093,9625,0804,3933,7033,911
  Inventory1.5%5,7545,6685,2935,3755,0554,8094,6164,5144,3494,2884,3134,5084,4844,5514,2294,1224,0423,9323,7533,8663,763
  Net PPE1.2%5,7355,6655,5695,4375,2985,2815,4135,2515,1885,1625,2215,0234,9384,8824,8284,7644,7564,7114,6754,5934,536
  Goodwill-1.5%40,82141,43641,42541,56566.0066.0061580.0080.0041,72041,96180538140,71439,84192.0092.0065.0039,95914660.00
Liabilities-2.5%38,44039,41039,28342,51641,18437,07138,26039,09139,59640,13741,48146,34245,57043,46339,81740,86940,33440,77139,48238,78938,436
  Current Liabilities6.8%9,6599,0479,05114,42214,46514,04912,3948,9277,8037,7648,50912,53412,07113,08610,3668,7358,1708,5188,4728,8538,463
  Long Term Debt-3.0%23,74124,46324,34422,21020,75317,48120,37224,29025,60725,95826,37826,50225,96722,86722,02124,73224,75224,80424,48623,67423,673
Shareholder's Equity0.2%51,46051,36651,48351,44152,05752,84352,72252,71352,15951,66451,60250,92850,31650,44350,87251,95350,71950,49750,21249,94149,714
  Retained Earnings0.0%30,25630,26530,39230,11729,79930,27630,25029,60728,97428,51128,59428,01527,52627,81728,13228,21027,01826,37726,27025,76925,171
  Additional Paid-In Capital0.0%24,58024,58724,59024,51324,44224,33524,56625,81426,05926,18426,31926,66526,48126,26126,16526,14426,17126,47026,53226,51827,048
Accumulated Depreciation----8,4898,1998,0437,9527,8237,7907,6467,4797,3757,2607,0706,8166,7436,6086,4256,2456,1535,976
Shares Outstanding0.0%1,3301,3301,3311,3301,3291,3291,3311,3441,3451,3451,3451,344---------
Minority Interest-0.5%187188182177177170171171168178174170152147135145141134121112107
Float-----115,500---161,200---135,300---141,300---120,800
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-24.5%6618752,4601,5749221,0832,0572,2281,7691,2921,7452,3561,8612781,4502,4071,8671,5102,0872,0551,163
  Share Based Compensation100.0%14673.0075.0081.0013762.0072.0078.0014069.0069.0065.0014070.0062.0066.0010861.0062.0060.00104
Cashflow From Investing21.3%-424-539-475-287-1,146-1,585271-437-709-7841,919-2,773-2,0208.00365-1,801-1,216-551-529-1,009121
Cashflow From Financing82.0%-90.00-501-4,890-2,1343,014-950-1,949-1,177-1,155-1,055-5,129-99832.001,959-1,310-873-1,741-274-860-1,268-1,730
  Dividend Payments0%918918905904904903843847847846781781780778724723723724671671674
  Buy Backs27.7%18914813163.0085.003331,4553723583115759.0068.00-1642365523281826721,171

MDT Income Statement

2023-10-27
Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Oct. 27, 2023
Oct. 28, 2022
Oct. 27, 2023
Oct. 28, 2022
Income Statement [Abstract]    
Net sales$ 7,984$ 7,585$ 15,686$ 14,955
Costs and expenses:    
Cost of products sold, excluding amortization of intangible assets2,7612,5355,3905,051
Research and development expense6986761,3651,368
Selling, general, and administrative expense2,6862,6175,2995,184
Amortization of intangible assets425421855844
Restructuring charges, net40309444
Certain litigation charges6501050
Other operating income, net(31)(97)(30)(62)
Operating profit1,3401,4042,6082,528
Other non-operating income, net(154)(109)(230)(192)
Interest expense, net180118329282
Income before income taxes1,3131,3952,5102,438
Income tax provision4029598021,072
Net income9114351,7081,367
Net income attributable to noncontrolling interests(2)(8)(8)(10)
Net income attributable to Medtronic$ 909$ 427$ 1,700$ 1,356
Basic earnings per share (usd per share)$ 0.68$ 0.32$ 1.28$ 1.02
Diluted earnings per share (usd per share)$ 0.68$ 0.32$ 1.28$ 1.02
Basic weighted average shares outstanding (shares)1,330.21,329.41,330.31,329.4
Diluted weighted average shares outstanding (shares)1,331.91,332.01,332.81,333.3

MDT Balance Sheet

2023-10-27
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Oct. 27, 2023
Apr. 28, 2023
Current assets:  
Cash and cash equivalents$ 1,311$ 1,543
Investments6,4236,416
Accounts receivable, less allowances and credit losses of $177 and $176, respectively5,9345,998
Inventories, net5,7545,293
Other current assets2,6582,425
Total current assets22,08121,675
Property, plant, and equipment, net5,7355,569
Goodwill40,82141,425
Other intangible assets, net14,06014,844
Tax assets3,4283,477
Other assets3,9623,959
Total assets90,08790,948
Current liabilities:  
Current debt obligations1,33920
Accounts payable2,1742,662
Accrued compensation1,7581,949
Accrued income taxes1,088840
Other accrued expenses3,2993,581
Total current liabilities9,6599,051
Long-term debt23,74124,344
Accrued compensation and retirement benefits1,0201,093
Accrued income taxes1,7772,360
Deferred tax liabilities686708
Other liabilities1,5561,727
Total liabilities38,44039,283
Commitments and contingencies (Note 16)
Shareholders’ equity:  
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,330,173,450 and 1,330,809,036 shares issued and outstanding, respectively00
Additional paid-in capital24,58024,590
Retained earnings30,25630,392
Accumulated other comprehensive loss(3,377)(3,499)
Total shareholders’ equity51,46051,483
Noncontrolling interests187182
Total equity51,64751,665
Total liabilities and equity$ 90,087$ 90,948
MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEwww.medtronic.com
 EMPLOYEES65535

Medtronic PLC Frequently Asked Questions


What is the ticker symbol for Medtronic PLC? What does MDT stand for in stocks?

MDT is the stock ticker symbol of Medtronic PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Medtronic PLC (MDT)?

As of Fri Feb 23 2024, market cap of Medtronic PLC is 113.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDT stock?

You can check MDT's fair value in chart for subscribers.

What is the fair value of MDT stock?

You can check MDT's fair value in chart for subscribers. The fair value of Medtronic PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Medtronic PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Medtronic PLC a good stock to buy?

The fair value guage provides a quick view whether MDT is over valued or under valued. Whether Medtronic PLC is cheap or expensive depends on the assumptions which impact Medtronic PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDT.

What is Medtronic PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, MDT's PE ratio (Price to Earnings) is 27.73 and Price to Sales (PS) ratio is 3.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Medtronic PLC's stock?

In the past 10 years, Medtronic PLC has provided 0.059 (multiply by 100 for percentage) rate of return.